Incorporating new data on colorectal cancer into nursing practice.
Treatment for colorectal cancer (CRC) has seen major advances, resulting in longer survival times for many patients. New data about improvements can appear daily in the form of updated journal articles, news reports, and study results reported at national and international oncology meetings. Practicing oncology nurses have a responsibility to keep current on treatments and symptom-management strategies for patients with cancer. Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are approved in metastatic CRC, and new data are helping to define appropriate patients. Additionally, symptom-management strategies for commonly administered agents in CRC have been refined for EGFR inhibitor-associated rash and neurotoxicity; new information on hypersensitivity and cetuximab also has been reported. This article will discuss the role of the oncology nurse in the management of patients with CRC.
Viale
Pamela Hallquist
PH
p.viale@comcast.net
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000451:nursing; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D011905:Genes, ras; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D009154:Mutation; D020258:Neurotoxicity Syndromes; D009859:Oncology Nursing; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D066246:ErbB Receptors; D008274:Magnesium; D002118:Calcium